Not a good buy right now for an impatient trader: trend structure is still bearish (SMA200 > SMA20 > SMA5) and there is no proprietary buy signal to lean on.
Short-term momentum is improving (MACD histogram positive/expanding), but price is sitting just below near-term resistance (~1.69–1.72); risk of chop/rejection is meaningful.
Bullish angle exists (new Buy initiation with $6 PT; improving YoY financial trends), but execution is better after a clean break and hold above ~1.72 rather than buying into resistance.
Net: HOLD now; only becomes a “buy right now” if it decisively pushes above ~1.72 and holds (breakout confirmation).
Trend/structure: Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) suggests the primary trend remains down despite today’s bounce.
Momentum: MACD histogram 0.0141 above zero and expanding = improving upside momentum (early reversal attempt).
RSI: RSI_6 ~59 (neutral-to-slightly-bullish), not overbought; supports the idea of a bounce but not a confirmed uptrend.
Levels to watch:
Support: Pivot ~1.642, then S1 ~1.592 (break below weakens the bounce).
Resistance: R1 ~1.691 then R2 ~1.722 (a breakout/hold above R2 would improve the “buy now” case).
Pattern-based near-term expectation (provided): modest edge near flat (next month slightly negative), which aligns more with “wait for confirmation” than “chase now.”
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (OI): Put/Call OI ratio 0.11 is very call-heavy (bullish skew in open interest).
Liquidity/flow today: Options volume is 0 (calls and puts), limiting how much real-time sentiment you can infer from today’s tape.
Volatility: Extremely elevated IV (30D IV ~686.77; IV percentile ~89.64, IV rank ~70.8) implies the market is pricing very large moves; this often corresponds to speculative behavior and/or event expectations, but also makes option premiums expensive.
Technical Summary
Sell
8
Buy
8
Positive Catalysts
with a Buy rating and a $6 price target (strong upside narrative vs. $1.67).
Neutral/Negative Catalysts
Primary trend still bearish (moving averages stacked bearishly), increasing the odds of failed rallies.
No recent news in the past week; lack of a near-term catalyst can keep the stock range-bound.
Options market is highly implied-volatility priced (very high IV), and today’s option volume is zero—signals can be noisy/illiquid.
No notable hedge fund or insider trend signals recently (both neutral), reducing “smart money confirmation.”
Net income: -$12.708M, improved 61.06% YoY (still deeply loss-making, but narrowing losses).
EPS: -$0.17, improved 6.25% YoY.
Gross margin: 34.24%, up 49.72% YoY (meaningful margin improvement trend).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: 2026-02-02 Maxim initiated coverage with Buy and $6 price target.
Wall Street pros view (bull case): large implied upside vs. current price, improving revenue and margin trajectory.
Wall Street cons view (bear case): still significant losses; without clear near-term catalysts and with a bearish technical structure, the stock can remain pressured or choppy.
Politicians/congress: No recent congress trading data available in the last 90 days (no signal from that channel).
Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is 5 USD with a low forecast of 5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is 5 USD with a low forecast of 5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.640
Low
5
Averages
5
High
5
Current: 1.640
Low
5
Averages
5
High
5
Maxim
NULL -> Buy
initiated
$6
AI Analysis
2026-02-02
Reason
Maxim
Price Target
$6
AI Analysis
2026-02-02
initiated
NULL -> Buy
Reason
Maxim initiated coverage of InspireMD with a Buy rating and $6 price target.
Piper Sandler
Overweight
downgrade
$4
2025-05-12
Reason
Piper Sandler
Price Target
$4
2025-05-12
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on InspireMD to $4 from $4.50 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results with sales above its expectations. The company pushed out expectations for FDA approval for its CGuard Prime stent to Q3 2025 from the first half of 2025 due to circumstances beyond the company's control. There was also a slight wiggle to expected U.S. launch timelines for the company's SwitchGuard TCAR system in development to late 2026, Piper adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NSPR
